Skip to main content
main-content

Neurology

ECTRIMS 2019

medwireNews attended ECTRIMS 2019 in Stockholm. Watch our expert interviews on the major trials.

Expert interviews from ECTRIMS 2019

13-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Sustained reduction in disability progression with ocrelizumab in patients with primary progressive MS

Jerry Wolinsky discusses findings from the open-label extension phase of the phase III ORATORIO trial highlighting the benefits of early ocrelizumab treatment on disability progression in patients with primary progressive multiple sclerosis (10:24).

13-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Support for newer drug-modifying therapies in initial treatment of paediatric MS

Kristen Krysko gives her findings on the real-world effectiveness of newer and injectable drug-modifying therapies as a guide to which treatments to initiate in children with multiple sclerosis (3:06).

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Myelin-specific CD8+ T-cell activation increased in MS

Joseph Sabatino discusses research showing a unique multiple sclerosis phenotype in the form of increased myelin-specific CD8+ T-cell activation and a role for anti-CD20 therapy (5:15).

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Perivascular inflammation and active white matter lesions linked to rapid MS progression

Damiano Marastoni explains how factors involved in white matter chronic inflammation play a key role in rapid MS disease progression (2:26).

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Prolonged exposure to disease-modifying therapies reduces the risk for disability progression in RRMS

Giuseppe Lucisano reports real-world data showing protection against disability progression in patients with relapsing-remitting multiple sclerosis over more than 10 years of follow-up (3:19).

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Timely and continuous therapy reduces conversion to progressive MS

Pietro Iaffaldano comments on real-world data showing risk factors associated with increased conversion from relapsing-remitting multiple sclerosis to secondary progressive disease (4:31).

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Hypogammaglobulinemia risk increased with rituximab in MS

Susanna Hallberg highlights hypogammaglobulinaemia as an important side effect of long-term rituximab treatment in MS, and makes recommendations on how to manage it in patients (2:32).

Twitter Icon Follow medwireNews

Click here
Image Credits